PMID: 33580918
Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG.Pediatr Blood Cancer. 2021 Feb 13:e28936. doi: 10.1002/pbc.28936. Online ahead of print.PMID: 33580918
PMID: 33231291
Brill R, Uller W, Huf V, Müller-Wille R, Schmid I, Pohl A, Häberle B, Perkowski S, Funke K, Till AM, Lauten M, Neumann J, Güttel C, Heid E, Ziermann F, Schmid A, Hüsemann D, Meyer L, Sporns PB, Schinner R, Schmidt VF, Ricke J, Rössler J, Kapp FG, Wohlgemuth WA, Wildgruber M.Int J Cancer. 2021 May 1;148(9):2345-2351. doi: 10.1002/ijc.33406. Epub 2020 Dec 3.PMID: 33231291
PMID: 29405800
Sirolimus-induced regression of a large orbital lymphangioma.
Lagrèze WA, Joachimsen L, Gross N, Taschner C, Rössler J.Orbit. 2019 Feb;38(1):79-80. doi: 10.1080/01676830.2018.1436569. Epub 2018 Feb 6.PMID: 29405800
PMID: 27706796
Rössler J, Geiger J, Földi E, Adams DM, Niemeyer CM.Int J Dermatol. 2017 Apr;56(4):e72-e75. doi: 10.1111/ijd.13419. Epub 2016 Oct 5.PMID: 27706796 No abstract available.
PMID: 27167017
Bessis D, Vernhet H, Bigorre M, Quéré I, Rössler J.JAMA Dermatol. 2016 Sep 1;152(9):1058-9. doi: 10.1001/jamadermatol.2016.1008.PMID: 27167017 No abstract available.